An observational study in Venous Thromboembolism, sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-01.
Sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (part of Daiichi Sankyo) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Venous Thromboembolism by Daiichi Sankyo — none open to participants now, none under way, none of them phase 3. Venous Thromboembolism · Daiichi Sankyo.
Among the 16 studies in Venous Thromboembolism by Daiichi Sankyo, this one is one of 3 that started in 2016, is one of 3 observational ones, and was the 14th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →None of the 16 studies in Venous Thromboembolism by Daiichi Sankyo is open now. The open studies under Venous Thromboembolism, anywhere →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 7
First in 2006; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,809 is above the median of 700 across 283 observational studies indexed under Venous Thromboembolism.
Median enrollment 523 across the 13 interventional studies, 1,197 across the 3 observational. Of the 16 that completed or were terminated, 14 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company, one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Venous Thromboembolism by Daiichi Sankyo, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
According to current guidelines, duration of anticoagulant treatment after a venous thromboembolic event varies from 3 months to indefinite treatment depending on the estimated risks of venous thromboembolism (VTE) recurrence and bleeding. Current data for edoxaban are limited to a maximum treatment duration of 12 months (Hokusai-VTE; N Engl J Med. 2013; 369:1406-15).
Therefore, this study aims to gather further insight into efficacy (i.e. symptomatic recurrent VTE) and safety (i.e. bleeding events, liver adverse events, all-cause mortality and other drug related adverse events) of extended treatment with edoxaban up to 18 months in an unselected patient population in routine clinical practice.
Real-world evidence data in routine clinical practice use of edoxaban up to 18 months will be collected in 2,700 patients, treated by specialized as well as non-specialized physicians in hospitals and office based centres in 8 European countries. Patients from different countries and care settings (primary care and secondary care, different specialties) will be enrolled in this post-authorization safety study. Documentation of baseline and follow up information at 1, 3, 6, 12, and 18 months (only when available) will be collected. In addition, recurrence of symptomatic VTE and death will be captured retrospectively at time point of Last Patient Out per country.
Patients who discontinue permanently edoxaban during the observational period will be followed up according to the same scheme.
All patients with established initial or recurrent acute symptomatic VTE (distal or proximal deep vein thrombosis/pulmonary embolism) treated with edoxaban according to the Summary of Product Characteristics (SmPC). To ensure that the physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban. Patients must have provided written informed consent for participation in the study (ICF) and should not participate simultaneously in any interventional study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with established initial or recurrent acute symptomatic VTE treated with edoxaban according to the Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
Drug: Edoxaban
Prescribed according to approved label
Also known as: Lixiana
Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall
Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. For the overall symptomatic VTE, precentage of participants (including 95% confidence intervals) were calculated.
Time frame: Baseline up to end of observation period (18 months)
Number of Participants With Bleeding Events (Adjudicated) While On Edoxaban Treatment
Descriptive statistics were used to report the number of participants with bleeding events. For the analysis of bleeding events, absolute number of participants were calculated.
Time frame: Baseline up to end of observation period (18 months)
Percentage of Participants Experiencing At Least 1 Real World Safety Event - Overall
Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. For recurrent VTE and real world safety events, absolute and relative frequencies (including 95% confidence intervals) were calculated.
Time frame: Baseline up to end of observation period (18 months)
Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - On Edoxaban Treatment
Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. For symptomatic VTE recurrence, percentage of participants (95% confidence intervals) were calculated.
Time frame: Baseline up to end of observation period (18 months)
Total Number of Venous Thromboembolism Recurrences By Type - Overall
Descriptive statistics were used to describe the number of VTE events reported by the patient. For VTE recurrences, absolute number of VTE events were calculated.
Time frame: Baseline up to end of observation period (18 months)
Duration of Venous Thromboembolism Recurrences, by Type - Overall
Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE recurrences, median duration of VTE events (interquartile range) were calculated.
Time frame: Baseline up to end of observation period (18 months)
Total Number of Venous Thromboembolism Recurrences (On Edoxaban Treatment)
Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. For VTE recurrences, absolute number of VTE recurrences were calculated.
Time frame: Baseline up to end of observation period (18 months)
Duration of Venous Thromboembolism Events (On Edoxaban Treatment)
Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE events, median duration of VTE events (interquartile range) were calculated.
Time frame: Baseline up to end of observation period (18 months)
Number of Participants With Risk Factors for Thromboembolic Events at Baseline
Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. For risk factors for thromboembolic events, absolute number of participants with risk factors (percentage) were calculated.
Time frame: at Baseline
Duration of Edoxaban Treatment
Descriptive statistics were used to report the duration of edoxaban treatment.
Time frame: Baseline up to end of observational period (18 months)
Number of Stroke Events
Descriptive statistics were used to report the number of stroke events. For stroke events, absolute number of stroke events were calculated.
Time frame: Baseline up to end of observation period (18 months)
Number of Systemic Embolic Events - Overall
Descriptive statistics were used to report the number of systemic embolic events (SEE). For SEE, absolute SEEs were calculated.
Time frame: Baseline up to end of observation period (18 months)
Overview of Participants With Adverse Drug Reactions
Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.
Time frame: Baseline up to end of observation period (18 months)
Number of Participants With Adverse Drug Reactions by Preferred Term (≥0.2%)
Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.
Time frame: Baseline up to end of observational period (18 months)
Number of Participants With Pre-defined Adverse Drug Reactions
Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.
Time frame: Baseline up to end of observation period (18 months)
A total of 2809 participants were included in the All Documented Patient Set defined as participants with a signed ICF and trustworthy data at sites in Germany, Austria, Switzerland, Belgium, The Netherlands, United Kingdom, Ireland, and Italy; a total of 2655 participants were included in the Baseline Analysis Set and a total of 2644 participants were included in the Full Analysis Set.
| Milestone | ETNA-VTE |
|---|---|
| Started | 2655 |
| Full analysis set | 2644 |
| Completed | 2325 |
| Not completed | 330 |
| Withdrew: Withdrawal by subject | 52 |
| Withdrew: Transfer to another institution | 6 |
| Withdrew: Lost to follow-up | 135 |
| Withdrew: Death | 98 |
| Withdrew: Other reason for premature termination | 32 |
| Withdrew: Missing reason for termination | 7 |
Descriptive statistics were used to report the number of participants with at least 1 symptomatic VTE recurrence. Recurrent VTE events were based on adjudicated events. For the overall symptomatic VTE, precentage of participants (including 95% confidence intervals) were calculated.
| Percentage of VTE recurrence | ETNA-VTE |
|---|---|
| Percentage of Participants With At Least 1 Symptomatic Venous Thromboembolism Recurrence - Overall | 3.8 (3.09 to 4.58) |
Descriptive statistics were used to report the number of participants with bleeding events. For the analysis of bleeding events, absolute number of participants were calculated.
| participants | ETNA-VTE |
|---|---|
| Participants with any bleeding events | 304 (10.31 to 12.78) |
| At least 1 major bleeding event | 38 (0.99 to 1.92) |
| Clinically relevant non-major bleeding event | 82 |
| Minor | 300 |
| Gastrointestinal bleeding event | 77 |
| Epidural or subdural haematoma bleeding event | 4 |
| Intra-ocular bleeding event | 5 |
| Intra-articular bleeding event | 3 |
| Pleural bleeding event | 1 |
| Other bleeding event | 319 |
| Spontaneous bleeding | 287 |
| Provoked bleeding | 115 |
| Unknown bleeding | 18 |
Descriptive statistics were used to report the number of participants experiencing recurrent VTE and at least 1 real world safety event. VTE recurrence data were reported by recurrent deep vein thrombosis (DVT), recurrent pulmonary embolism (PE) with DVT, and recurrent PE only. Recurrent VTE events were based on adjudicated events. Real world safety events included all-cause death, cardiovascular (CV)-related death, VTE-related death, stroke, systemic embolic event, and hospitalization related to CV. For recurrent VTE and real world safety events, absolute and relative frequencies (including 95% confidence intervals) were calculated.
| Percentage of real world safety events | ETNA-VTE |
|---|---|
| Recurrent DVT only | 2.3 (1.77 to 2.95) |
| Recurrent PE with DVT | 0.3 (0.11 to 0.54) |
| Recurrent PE only | 1.2 (0.80 to 1.66) |
| All-cause death | 3.6 (2.92 to 4.37) |
| Cardiovascular-related death | 0.9 (0.55 to 1.30) |
| Venous thromboembolism-related death | 0 (0 to 0.21) |
| Stroke | 1.0 (0.64 to 1.44) |
| Systemic embolic event | 0.1 (0.01 to 0.27) |
| Hospitalization related to CV | 9.6 (8.47 to 10.75) |
Descriptive statistics were used to report the number of participants with overall symptomatic VTE recurrence. VTE recurrence data were further reported by recurrent deep venous thrombosis (DVT), recurrent pulmonary embolism (PE) with deep venous thrombosis (DVT), and recurrent PE only. Recurrent VTE events were based on adjudicated events. For symptomatic VTE recurrence, percentage of participants (95% confidence intervals) were calculated.
| Percentage of VTE recurrence | ETNA-VTE |
|---|---|
| Recurrent VTE | 1.4 (0.99 to 1.92) |
| Recurrent DVT only | 1.0 (0.67 to 1.48) |
| Recurrent PE with DVT | 0 (0 to 0.21) |
| Recurrent PE only | 0.3 (0.16 to 0.65) |
| All-cause death | 1.9 (1.41 to 2.49) |
| CV-related death | 0.4 (0.21 to 0.74) |
| VTE-related death | 0 (0 to 0.21) |
| Stroke | 0.6 (0.32 to 0.93) |
| Systemic embolic event | 0 (0 to 0.21) |
| Hospitalization-related to cardiovascular | 6.3 (5.42 to 7.31) |
Descriptive statistics were used to describe the number of VTE events reported by the patient. For VTE recurrences, absolute number of VTE events were calculated.
| VTE recurrences | ETNA-VTE |
|---|---|
| Total number of VTE recurrences | 105 |
| Deep vein thrombosis (DVT) only | 64 |
| Pulmonary embolism with DVT | 7 |
| Pulmonary embolism only | 32 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE recurrences, median duration of VTE events (interquartile range) were calculated.
| days | ETNA-VTE |
|---|---|
| Total number of VTE recurrences | 18.0 (8.0 to 93.0) |
| Deep vein thrombosis (DVT) only | 44.5 (8.0 to 95.0) |
| Pulmonary embolism with DVT | 8.0 (5.0 to 146.0) |
| Pulmonary embolism only | 16.0 (8.0 to 93.0) |
Descriptive statistics were used to assess the number of recurrent VTE events reported by the patient. For VTE recurrences, absolute number of VTE recurrences were calculated.
| VTE recurrences | ETNA-VTE |
|---|---|
| Total number of VTE recurrences | 39 |
| Deep vein thrombosis (DVT) only | 28 |
| Pulmonary embolism with DVT | 1 |
| Pulmonary embolism only | 9 |
Descriptive statistics were used to assess the duration of VTE events reported by the patient. For VTE events, median duration of VTE events (interquartile range) were calculated.
| days | ETNA-VTE |
|---|---|
| Total number of VTE recurrences | 11.0 (8.0 to 20.0) |
| Deep vein thrombosis (DVT) only | 9.5 (8.0 to 20) |
| Pulmonary embolism with DVT | 0 (0 to 0) |
| Pulmonary embolism only | 15.0 (8.0 to 16.0) |
Descriptive statistics were used to assess the number of participants with risk factors for thromboembolic events. For risk factors for thromboembolic events, absolute number of participants with risk factors (percentage) were calculated.
| Participants | ETNA-VTE |
|---|---|
| Puerperium | 9 |
| Prolonged immobilisation | 401 |
| >5 days in bed | 218 |
| History of major surgery trauma | 359 |
| Known thrombophilic conditions | 111 |
Descriptive statistics were used to report the duration of edoxaban treatment.
| Participants | ETNA-VTE |
|---|---|
| Month 1 ongoing | 2527 |
| Month 3 ongoing | 2346 |
| Month 6 ongoing | 1842 |
| Month 12 ongoing | 1272 |
| Month 18 ongoing | 713 |
| Participants off edoxaban treatment at 18 months | 1910 |
Descriptive statistics were used to report the number of stroke events. For stroke events, absolute number of stroke events were calculated.
| events | ETNA-VTE |
|---|---|
| Overall treatment: Total number of stroke events | 27 |
| Overall treatment: Ischemic events | 17 |
| Overall treatment: Haemorrhagic events | 5 |
| Overall treatment: Unknown events | 5 |
| On treatment: Total number of stroke events | 16 |
| On treatment: Ischemic events | 12 |
| On treatment: Haemorrhagic events | 3 |
| On treatment: Unknown events | 1 |
Descriptive statistics were used to report the number of systemic embolic events (SEE). For SEE, absolute SEEs were calculated.
| Systemic embolic events | ETNA-VTE |
|---|---|
| Upper/lower extremity | 1 |
| Renal | 1 |
Descriptive statistics were used to report an overview of participants with adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.
| Participants | ETNA-VTE |
|---|---|
| Death due to ADR | 2 |
| Participants with at least 1 ADR | 142 |
| Participants with at least 1 serious ADR | 59 |
| Study discontinuation due to ADR | 0 |
Adverse drug reactions were reported and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.
| Participants | ETNA-VTE |
|---|---|
| Haemorrhage | 35 |
| Gastrointestinal haemorrhage | 12 |
| Menorrhagia | 12 |
| Epistaxis | 11 |
| Fatigue | 8 |
| Nausea | 8 |
| Dizziness | 7 |
| Rash | 7 |
| Headache | 5 |
| Pruritus | 5 |
Descriptive statistics were used to report the number of participants with pre-defined adverse drug reactions (ADR). ADRs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 20.1.
| Participants | ETNA-VTE |
|---|---|
| Stroke | 2 |
| Bleeding events | 75 |
| Systemic embolic events | 0 |
| Non-valvular atrial fibrillation | 0 |
| Malignancy | 0 |
| Others | 4 |
Collected over Treatment-emergent adverse events were not assessed in this non-interventional (observational) study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETNA-VTE | 98/2,644 (3.7%) | — | — |
Demographic and baseline characteristics were assessed in the Full Analysis Set.
| Age, Continuous(years) | ETNA-VTE |
|---|---|
| Median | 65.0 (52.0 to 76.0) |
| Age, Customized(Participants) | ETNA-VTE |
|---|---|
| <65 years | 1312 |
| ≥65 and <75 years | 593 |
| ≥75 years | 739 |
| Sex: Female, Male(Participants) | ETNA-VTE |
|---|---|
| Female | 1231 |
| Male | 1413 |
| Race and Ethnicity Not Collected(Participants) | ETNA-VTE |
|---|
| Region of Enrollment(participants) | ETNA-VTE |
|---|---|
| Germany | 722 |
| Austria | 182 |
| Switzerland | 84 |
| Belgium | 372 |
| Netherlands | 321 |
| United Kingdom | 113 |
| Ireland | 17 |
| Italy | 833 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2016 to primary completion in Dec 2020, 55 months.
Results were first posted in May 2022, 1 year 5 months after primary completion.
Of 118 observational studies under Venous Thromboembolism, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 75. This study's 55 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company →